Insomnia Outcomes May Vary by Measurement Method
Smartphone-based symptom tracking highlights gaps in how insomnia treatments are evaluated.
-
By
-
Henry Thomas
-
February 12, 2026
-
Clinical Scorecard: Insomnia Outcomes May Vary by Measurement Method
At a Glance
| Category | Detail |
|---|
| Condition | Chronic Insomnia |
| Key Mechanisms | Suvorexant treatment effects on daytime symptoms |
| Target Population | Older adults aged 60 to 85 years with moderate to severe insomnia |
| Care Setting | Clinical trial setting |
Key Highlights
- Suvorexant reduced insomnia severity compared to placebo.
- Traditional questionnaires missed daytime effects of treatment.
- Ecological momentary assessment (EMA) revealed time-of-day-specific changes.
- Participants reported greater morning fatigue and reduced alertness earlier in the day.
- EMA showed feasibility for tracking symptoms in older adults.
Guideline-Based Recommendations
Diagnosis
- Consider comprehensive assessment of insomnia symptoms, including daytime effects.
Management
- Utilize EMA for a nuanced understanding of treatment effects.
Monitoring & Follow-up
- Monitor daytime symptoms and mood alongside traditional measures.
Risks
- Be aware of potential mood-related effects associated with orexin antagonists.
Patient & Prescribing Data
Older adults with chronic insomnia
Suvorexant may have variable effects on daytime fatigue and cognition.
Clinical Best Practices
- Incorporate EMA into routine assessments for insomnia treatment.
- Balance perceived benefits of treatment against adverse daytime effects.
References
